Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Oct 9, 2003

Keywords

ClinConnect Summary

This clinical trial is focused on collecting tissue samples from patients with solid tumors or blood disorders, as well as their family members who are compatible donors. The main goal is to gather biological materials to help researchers better understand these diseases, evaluate existing treatments, and explore new therapies or ways to prevent these conditions. The study is open to patients aged 2 years and older who are being screened for or are already part of a treatment study at the NIH Clinical Center. Additionally, family members who may be suitable donors for stem cell transplants can also participate.

If you join the trial, you can expect to provide samples such as blood, urine, stool, or tissue biopsies as part of your regular medical care. In some cases, additional samples may be requested. For adult participants, there is also an option to donate a larger amount of white blood cells through a procedure called leukapheresis, which involves separating white blood cells from the rest of your blood using a special machine. This trial is currently recruiting participants, and it offers an opportunity to contribute to important research that could improve the understanding and treatment of cancer and blood disorders.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• • The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder, and is being screened at the NIH for eligibility for an NIH protocol.
• • OR
• • The subject carries the diagnosis of malignant solid tumor or a malignant or non-malignant hematologic disorder, and is already enrolled on a protocol at the NIH Clinical Center.
• • OR
• • The subject is a related HLA-compatible family member of a patient (bearing a diagnosis of malignant solid tumor or a malignant or non-malignant hematologic) being evaluated for or already enrolled on a protocol at the NIH Clinical Center and is identified as a potentially suitable donor of allogeneic hematopoietic stem cells for transplantation.
• • OR
• • The subject carries the diagnosis of malignant solid tumor or a malignant or non malignant hematologic disorder or a bone marrow failure condition and is not available to participate in an NIH Clinical Center treatment protocol, or travel to the NIH clinical center, but is referred for participation through their home health care provider.
• • The subject or the subject's Legally Authorized Representative (LAR) is able to understand the investigational nature of the study and provide informed consent after initial counseling by an AI. Separate consent forms for interventional or surgical procedures will be obtained after explanation of the specific procedure.
• • Age 2 years and older (no upper limit)
• EXCLUSION CRITERIA:
• • Subjects or LAR unable to comprehend the investigational nature of the protocol.
• • Age less than 2 years